QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

2 evidence topics · 2 sources

Expanded access

“Palvella will consider requests from licensed treating physicians for access to investigational products in development for patient treatment purposes on a case-by-case basis.” (opens the source at this quote in a new tab)

Patient-access infrastructure

“The Company continues to build these organizations through the addition of field commercial leaders, medical science liaisons, and patient access liaisons.” (opens the source at this quote in a new tab)